title: MiR-30a Decreases Multidrug Resistance (MDR) of Gastric Cancer Cells.
abstract: BACKGROUND The effectiveness of chemotherapy for gastric cancer is largely limited by either intrinsic or acquired drug resistance. In this study, we aimed to explore the association between miR-30a dysregulation and multidrug resistance (MDR) in gastric cancer cells. MATERIAL AND METHODS We recruited 20 patients with advanced gastric cancer. Chemosensitivity was assessed after completion of the chemotherapy. SGC-7901 and SGC-7901/DDP cells were transfected for miR-30a overexpression or knockdown. Then, MTT assay was performed to assess the IC50 of DPP and 5-FU in SGC-7901 and SGC-7901/DDP cells. Flow cytometry analysis was used to detect DPP- and 5-FU-induced cell apoptosis. Western blot analysis and immunofluorescence staining were used to assess EMT of the cells. RESULTS MiR-30a was significantly downregulated in the chemoresistant tissues. In both SGC-7901 and SGC-7901/DDP cells, miR-30a overexpression decreased the expression of P-gp, a MDR-related protein. MTT assay and flow cytometry analysis showed that miR-30a inhibition increased chemoresistance, while miR-30a overexpression decreased chemoresistance in gastric cancer cells. Both Western blot analysis and immunofluorescence staining confirmed that miR-30a inhibition decreased E-cadherin but increased N-cadherin in SGC-7901 cells, while miR-30a overexpression increased E-cadherin but decreased N-cadherin in SGC-7901 cells. CONCLUSIONS MiR-30a can decrease multidrug resistance (MDR) of gastric cancer cells. It is also an important miRNA modulating EMT of the cancer cells.
authors.affiliation: Department of Gastroenterology, Cangzhou Central Hospital, Cangzhou, Hebei, China (mainland).
authors.forename: Chunying
authors.initials: C
authors.lastname: Li
authors.affiliation: Department of Nuclear Medicine, Cangzhou Central Hospital, Cangzhou, Hebei, China (mainland).
authors.forename: Jinhai
authors.initials: J
authors.lastname: Zou
authors.affiliation: Department of Gastroenterology, Cangzhou Central Hospital, Cangzhou, Hebei, China (mainland).
authors.forename: Guoqi
authors.initials: G
authors.lastname: Zheng
authors.affiliation: Department of Gastroenterology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (mainland).
authors.forename: Jiankun
authors.initials: J
authors.lastname: Chu
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D015820:Cadherins / Q000235:genetics / Q000378:metabolism; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002945:Cisplatin / Q000008:administration & dosage; D015536:Down-Regulation / Q000187:drug effects; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D058750:Epithelial-Mesenchymal Transition; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D055785:Gene Knockdown Techniques; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000096:biosynthesis / Q000235:genetics*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D014162:Transfection
chemical_list: D015820:Cadherins; C546086:MIRN30b microRNA, human; D035683:MicroRNAs; D002945:Cisplatin; D005472:Fluorouracil